Literature DB >> 15509633

Inhalation and dermal exposure among asphalt paving workers.

M D McClean1, R D Rinehart, L Ngo, E A Eisen, K T Kelsey, R F Herrick.   

Abstract

The primary objective of this study was to identify determinants of inhalation and dermal exposure to polycyclic aromatic compounds (PACs) among asphalt paving workers. The study population included three groups of highway construction workers: 20 asphalt paving workers, as well as 12 millers and 6 roadside construction workers who did not work with hot-mix asphalt. During multiple consecutive work shifts, personal air samples were collected from each worker's breathing zone using a Teflon filter and cassette holder connected in series with an XAD-2 sorbent tube, while dermal patch samples were collected from the underside of each worker's wrist. All exposure samples were analyzed for PACs, pyrene and benzo[a]pyrene. Inhalation and dermal PAC exposures were highest among asphalt paving workers. Among paving workers, inhalation and dermal PAC exposures varied significantly by task, crew, recycled asphalt product (RAP) and work rate (inhalation only). Asphalt mix containing high RAP was associated with a 5-fold increase in inhalation PAC exposures and a 2-fold increase in dermal PAC exposure, compared with low RAP mix. The inhalation PAC exposures were consistent with the workers' proximity to the primary source of asphalt fume (paver operators > screedmen > rakers > roller operators), such that the adjusted mean exposures among paver operators (5.0 microg/m3, low RAP; 24 microg/m3, high RAP) were 12 times higher than among roller operators (0.4 microg/m3, low RAP; 2.0 microg/m3, high RAP). The dermal PAC exposures were consistent with the degree to which the workers have actual contact with asphalt-contaminated surfaces (rakers > screedmen > paver operators > roller operators), such that the adjusted mean exposures among rakers (175 ng/cm2, low RAP; 417 ng/cm2, high RAP) were approximately 6 times higher than among roller operators (27 ng/cm2, low RAP; 65 ng/cm2, high RAP). Paving task, RAP content and crew were also found to be significant determinants of inhalation and dermal exposure to pyrene. The effect of RAP content, as well as the fact that exposures were higher among paving workers than among millers and roadside construction workers, suggests that the PAC and pyrene exposures experienced by these paving workers were asphalt-related.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15509633     DOI: 10.1093/annhyg/meh062

Source DB:  PubMed          Journal:  Ann Occup Hyg        ISSN: 0003-4878


  17 in total

1.  A case-control study of asphalt and tar exposure and lung cancer in minorities.

Authors:  Michael D McClean; Karl T Kelsey; Jennette D Sison; Charles P Quesenberry; Margaret R Wrensch; John K Wiencke
Journal:  Am J Ind Med       Date:  2011-08-31       Impact factor: 2.214

2.  Levels of 1-hydroxypyrene in urine of people living in an oil producing region of the Andean Amazon (Ecuador and Peru).

Authors:  Jena Webb; Oliver T Coomes; Donna Mergler; Nancy A Ross
Journal:  Int Arch Occup Environ Health       Date:  2017-09-22       Impact factor: 3.015

3.  Biomarker variance component estimation for exposure surrogate selection and toxicokinetic inference.

Authors:  Jon R Sobus; Joachim D Pleil; Michael D McClean; Robert F Herrick; Stephen M Rappaport
Journal:  Toxicol Lett       Date:  2010-09-22       Impact factor: 4.372

4.  Metabolism and excretion rates of parent and hydroxy-PAHs in urine collected after consumption of traditionally smoked salmon for Native American volunteers.

Authors:  Oleksii Motorykin; Lisandra Santiago-Delgado; Diana Rohlman; Jill E Schrlau; Barbara Harper; Stuart Harris; Anna Harding; Molly L Kile; Staci L Massey Simonich
Journal:  Sci Total Environ       Date:  2015-02-05       Impact factor: 7.963

5.  Comparing urinary biomarkers of airborne and dermal exposure to polycyclic aromatic compounds in asphalt-exposed workers.

Authors:  Jon R Sobus; Michael D McClean; Robert F Herrick; Suramya Waidyanatha; Leena A Nylander-French; Lawrence L Kupper; Stephen M Rappaport
Journal:  Ann Occup Hyg       Date:  2009-07-14

6.  Investigation of PAH biomarkers in the urine of workers exposed to hot asphalt.

Authors:  Jon R Sobus; Michael D McClean; Robert F Herrick; Suramya Waidyanatha; Frank Onyemauwa; Lawrence L Kupper; Stephen M Rappaport
Journal:  Ann Occup Hyg       Date:  2009-07-14

7.  A case-control study of lung cancer nested in a cohort of European asphalt workers.

Authors:  Ann Olsson; Hans Kromhout; Michela Agostini; Johnni Hansen; Christina Funch Lassen; Christoffer Johansen; Kristina Kjaerheim; Sverre Langård; Isabelle Stücker; Wolfgang Ahrens; Thomas Behrens; Marja-Liisa Lindbohm; Pirjo Heikkilä; Dick Heederik; Lützen Portengen; Judith Shaham; Gilles Ferro; Frank de Vocht; Igor Burstyn; Paolo Boffetta
Journal:  Environ Health Perspect       Date:  2010-06-09       Impact factor: 9.031

8.  Personal breathing zone exposures among hot-mix asphalt paving workers; preliminary analysis for trends and analysis of work practices that resulted in the highest exposure concentrations.

Authors:  Linda V Osborn; John E Snawder; Anthony J Kriech; Jennifer M Cavallari; Michael D McClean; Robert F Herrick; Gary R Blackburn; Larry D Olsen
Journal:  J Occup Environ Hyg       Date:  2013       Impact factor: 2.155

9.  Urinary naphthalene and phenanthrene as biomarkers of occupational exposure to polycyclic aromatic hydrocarbons.

Authors:  J R Sobus; S Waidyanatha; M D McClean; R F Herrick; T J Smith; E Garshick; F Laden; J E Hart; Y Zheng; S M Rappaport
Journal:  Occup Environ Med       Date:  2008-11-18       Impact factor: 4.402

10.  Metabolites of the PAH diol epoxide pathway and other urinary biomarkers of phenanthrene and pyrene in workers with and without exposure to bitumen fumes.

Authors:  Anne Lotz; Beate Pesch; Gerhard Dettbarn; Monika Raulf; Peter Welge; Hans-Peter Rihs; Dietmar Breuer; Stefan Gabriel; Jens-Uwe Hahn; Thomas Brüning; Albrecht Seidel
Journal:  Int Arch Occup Environ Health       Date:  2016-08-10       Impact factor: 3.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.